Table 1 Baseline characteristics of the intention-to-treat ancillary amyloid blood MAPT study population (n = 483)

Subject characteristics

 Male gender, N (%)

40 (42.55)

27 (36.99)

26 (31.33)

24 (33.33)

20 (57.14)

20 (51.28)

18 (48.65)

22 (44.00)

 Age in years, mean (SD)

75.97 (4.77)

75.52 (4.64)

75.08 (4.44)

75.11 (3.96)

76.69 (4.78)

77.23 (4.45)

75.30 (4.52)

76.54 (4.69)

 Education, N (%)

  No diploma or primary school certificate

18 (19.35)

20 (28.17)

17 (20.99)

21 (29.17)

8 (22.86)

14 (36.84)

11 (29.73)

12 (24.49)

  Secondary education

35 (37.63)

19 (26.76)

27 (33.33)

16 (22.22)

14 (40.00)

15 (39.47)

15 (40.54)

17 (34.69)

  High-school diploma

16 (17.20)

8 (11.27)

17 (20.99)

12 (16.67)

4 (11.43)

2 (5.26)

2 (5.41)

8 (16.33)

  University level

24 (25.81)

24 (33.80)

20 (24.69)

23 (31.94)

9 (25.71)

7 (18.42)

9 (24.32)

12 (24.49)

 APOE ε4 carrier, N (%)

17 (20.24)

9 (14.06)

16 (21.33)

19 (28.79)

11 (34.38)

12 (32.43)

19 (55.88)

18 (39.13)

 DHA (μg/g RBC), mean (SD)

30.08 (7.97)

29.70 (9.43)

32.84 (9.76)

33.34 (10.48)

28.63 (9.69)

32.85 (10.20)

31.24 (10.15)

31.72 (9.43)

 Plasma Aβ42/40, mean (SD)

0.12 (0.02)

0.12 (0.01)

0.12 (0.01)

0.12 (0.01)

0.10 (0.01)

0.10 (0.01)

0.10 (0.01)

0.10 (0.01)

Cognition

 Cognitive composite score, mean (SD)

0.01 (0.66)

0.09 (0.60)

0.06 (0.68)

0.13 (0.57)

-0.26 (0.90)

-0.10 (0.68)

-0.21 (0.82)

-0.02 (0.57)

 MMSE total score/30, mean (SD)

28.27 (1.58)

28.18 (1.61)

27.95 (1.76)

28.21 (1.48)

27.86 (1.54)

27.72 (1.99)

27.84 (1.50)

27.50 (1.64)

 MMSE orientation score/10, mean (SD)

9.87 (0.42)

9.88 (0.41)

9.77 (0.55)

9.86 (0.39)

9.57 (0.74)

9.74 (0.55)

9.65 (0.68)

9.82 (0.48)

 CDR score, N (%)

  CDR = 0

63 (67.02)

38 (52.05)

40 (48.19)

41 (56.94)

16 (45.71)

19 (48.72)

19 (51.35)

20 (40.00)

  CDR = 0.5

31 (32.98)

35 (47.95)

43 (51.81)

31 (43.06)

19 (54.29)

20 (51.28)

18 (48.65)

30 (60.00)

 FCSRT scores, mean (SD)

  Free recall/48

26.87 (6.76)

27.51 (6.04)

27.24 (7.66)

27.43 (6.22)

25.20 (7.82)

27.33 (6.78)

24.41 (7.76)

25.92 (6.64)

  Total recall/48

44.38 (4.33)

45.63 (3.27)

44.80 (4.76)

45.35 (3.41)

43.91 (4.61)

44.87 (4.37)

44.57 (4.01)

44.78 (4.46)

  Delayed free recall/16

10.40 (2.83)

10.74 (2.72)

10.47 (3.11)

10.65 (3.00)

9.40 (3.94)

10.21 (3.18)

9.38 (3.62)

10.04 (2.88)

  Delayed total recall/16

15.19 (1.53)

15.42 (1.18)

15.29 (1.70)

15.46 (1.06)

14.74 (1.87)

15.36 (1.09)

14.92 (1.46)

15.28 (1.34)

 TMT A, mean (SD)

49.87 (17.93)

49.51 (22.23)

46.82 (19.14)

46.18 (17.73)

48.14 (19.74)

47.41 (13.44)

51.11 (20.93)

44.10 (10.56)

 TMT B, mean (SD)

128.86 (56.53)

129.40 (72.96)

114.72 (46.86)

112.30 (39.45)

139.94 (104.15)

134.05 (52.82)

131.53 (68.08)

116.32 (40.36)

 Code test score, mean (SD)

36.29 (9.58)

35.92 (10.20)

37.81 (10.52)

37.92 (9.32)

35.40 (9.14)

34.28 (9.58)

35.19 (11.58)

36.28 (7.86)

 COWAT score, mean (SD)

19.37 (6.22)

19.34 (6.90)

19.47 (6.75)

20.15 (6.68)

19.63 (7.50)

18.72 (5.69)

18.89 (6.11)

18.76 (5.91)

 CNT score, mean (SD)

24.78 (7.19)

25.95 (7.27)

26.20 (7.93)

26.15 (6.95)

23.54 (8.40)

24.31 (7.43)

24.08 (7.05)

25.16 (6.72)

Other measures

 ADCS-ADL PI /45; mean (SD)

39.16 (4.63)

39.03 (5.26)

39.17 (5.06)

38.54 (6.05)

38.68 (4.35)

39.49 (5.27)

39.51 (5.42)

39.72 (4.35)

 GDS, mean (SD)

2.92 (2.41)

3.08 (2.86)

3.57 (2.94)

3.01 (2.88)

2.57 (1.97)

3.23 (2.56)

2.81 (2.15)

3.08 (2.33)

 SPPB, mean (SD)

10.50 (1.53)

10.65 (1.72)

10.28 (1.74)

10.59 (1.55)

10.60 (1.63)

10.23 (1.31)

11.11 (1.37)

10.43 (1.65)

 3-year adherence ≥ 75%, N (%)

51 (54.26)

58 (84.06)

40 (48.19)

59 (89.39)

19 (55.88)

30 (93.75)

19 (52.78)

38 (82.61)